Center City Healthcare, LLC v. McKesson Plasma & Biologics LLC

CourtUnited States Bankruptcy Court, D. Delaware
DecidedJune 13, 2022
Docket21-50796
StatusUnknown

This text of Center City Healthcare, LLC v. McKesson Plasma & Biologics LLC (Center City Healthcare, LLC v. McKesson Plasma & Biologics LLC) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Center City Healthcare, LLC v. McKesson Plasma & Biologics LLC, (Del. 2022).

Opinion

IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: ) Ch. 11 ) CENTER CITY HEALTHCARE, LLC d/b/a ) Case No. 19-11466 (MFW) HAHNEMANN UNIVERSITY HOSPITAL, ) et al., ) (Jointly Administered) ) Debtors. ) ) CENTER CITY HEALTHCARE, LLC d/b/a ) Adv. Proc. No. 21-50796 HAHNEMANN UNIVERSITY HOSPITAL, ) (MFW) ST. CHRISTOPHER’S HEALTHCARE, LLC ) TPS III OF PA, LLC, TPS IV OF PA, ) and TPS V OF PA, LLC ) ) Plaintiffs, ) ) v. ) ) MCKESSON PLASMA & BIOLOGICS LLC ) & MCKESSON MEDICAL-SURGICAL, INC., ) ) Defendants. ) Re: D.I. 1, 18, 21 & 25 MEMORANDUM OPINION1 Before the Court is a motion to dismiss (the “Motion to Dismiss”) a Complaint seeking avoidance of preferential transfers, avoidance of fraudulent transfers, recovery of property, and disallowance of claims. For the reasons stated below, the Court will grant in part, and deny in part, the Motion to Dismiss. 1 The Court is not required to state findings of fact or conclusions of law pursuant to Rule 7052 of the Federal Rules of Bankruptcy Procedure. Instead, the facts recited are those averred in the Complaint, which must be accepted as true for the purposes of the Motion to Dismiss. Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). I. BACKGROUND On June 30 and July 1, 2019, Center City Healthcare, LLC and some of its affiliates (the “Debtors”) filed petitions under chapter 11 of the Bankruptcy Code. The Debtors employed EisnerAmper LLP (“EisnerAmper”), with Court approval, to provide interim management and operational services to the Debtors.2 As part of this role, EisnerAmper reviewed the Debtors’ financials for the ninety days prior to the Petition Date (the “Avoidance Period”). Based on that review, the Debtors concluded that several transfers (the “Transfers”) from the Debtors to McKesson Plasma & Biologics LLC (“McKesson Plasma”) and McKesson Medical- Surgical, Inc. (“McKesson Medical”) (collectively, the “Defendants”) were avoidable.3 On May 7 and May 26, 2021, the Debtors sent offers to the Defendants to settle these claims (the “Demand Letters”).4 The Defendants did not respond.5

2 D.I. 338. References to the docket in the main case are to “D.I. #” while references to the docket in this adversary proceeding are to “Adv. D.I. #.” 3 Adv. D.I. 1 ¶¶ 3, 33-34, 39, & Exs. B & C. 4 The Debtors attached the Demand Letters to their response. Adv. D.I. 21 at Ex. 1. In the Demand Letters, the Debtors outlined claims against the Defendants, delineated potentially applicable defenses to a preference action, proposed a settlement of the claims, and invited the Defendants to identify defenses upon which they would rely. Id. 5 Adv. D.I. 1 ¶ 36. 2 On June 23, 2021, the Debtors commenced a Complaint against the Defendants seeking to recover $853,284 in pre-petition payments made by the Debtors to the Defendants during the Avoidance Period.6 The Complaint seeks to avoid and recover those Transfers as preferences under Counts I & III, to avoid and recover those Transfers as fraudulent transfers under Counts II & III, and to disallow any claims that the Defendants may have against the Debtors under Count IV. On February 7, 2022, the Defendants filed the Motion to Dismiss pursuant to Rules 8 and 12 of the Federal Rules of Civil Procedure.7 On February 22, 2022, the Debtors filed a response.8 The Defendants filed a reply on March 1, 2022.9 The Motion to Dismiss is ripe for decision.

6 Exhibit A to the Complaint is a summary of the Transfers, Exhibit B sets forth the details of each of the Transfers to McKesson Plasma (totaling $790,414), and Exhibit C sets forth the details of each of the Transfers to McKesson Medical (totaling $62,870). Id. ¶¶ 32-34. Exhibits B and C include the applicable check number, the payment, wire or ACH identifying number, the payment date, the payment amount, the invoice number(s) to which each payment relates, the invoice date(s), and the invoice amount(s) paid. Id. 7 Adv. D.I. 18. The applicable Federal Rules of Civil Procedure are incorporated in the Federal Rules of Bankruptcy Procedure. Therefore, citations herein are to the Federal Rules of Civil Procedure. 8 Adv. D.I. 21. 9 Adv. D.I. 25. 3 II. JURISDICTION The Court has subject matter jurisdiction over this adversary proceeding. 28 U.S.C. § 1334(b). This action involves core claims. 28 U.S.C. § 157(b). The Defendants have consented to entry of an order by the Court on the Motion to Dismiss.10

III. DISCUSSION A. Standard of Review 1. Rule 12(b)(6) The Motion to Dismiss is brought under Rules 8(a) and 12(b)(6). Rule 8(a) requires a complaint to contain “a short and plain statement of the claim showing that the pleader is entitled to relief.”11 Rule 12(b)(6) provides for dismissal for “failure to state a claim upon which relief can be granted.”12 When a complaint is challenged by a motion to dismiss under Rule 12(b)(6), the complaint “does not need detailed factual allegations, [but] a plaintiff’s obligation to provide the ‘grounds’ of his ‘entitle[ment] to relief’ requires more than labels and conclusions, and a formulaic recitation of the

elements of a cause of action will not do.”13 To survive a 10 Adv. D.I. 18, 25. 11 Fed. R. Civ. P. 8(a). 12 Fed. R. Civ. P. 12(b)(6). 13 Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007). 4 motion to dismiss, the complaint must contain sufficient factual matter, accepted as true, “to state a claim to relief that is plausible on its face.”14 Two “working principles” underlie this pleading standard: First, the tenet that a court must accept a complaint’s allegations as true is inapplicable to threadbare recitals of a cause of action’s elements, supported by mere conclusory statements. Second, determining whether a complaint states a plausible claim is context specific, requiring the reviewing court to draw on its experience and common sense.15 Under this standard, a complaint must nudge claims “across the line from conceivable to plausible.”16 The court must draw all reasonable inferences in favor of the plaintiff,17 and the movant “bears the burden to show that the plaintiff’s claims are not plausible.”18 In weighing a motion to dismiss, the Third Circuit instructs courts to follow a three-part analysis. “First, the court must ‘tak[e] note of the elements a plaintiff must plead to state a 14 Id. at 570. 15 Iqbal, 556 U.S. at 663-64 (citation omitted). 16 Twombly, 550 U.S. at 570. 17 See, e.g., Alpizar-Fallas v. Favero, 908 F.3d 910, 914 (3d Cir. 2018). 18 UMB Bank, N.A. v. Sun Capital Partners V, LP (In re LSC Wind Down, LLC), 610 B.R. 779, 783 (Bankr. D. Del. 2020).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Santiago v. Warminster Township
629 F.3d 121 (Third Circuit, 2010)
U.S. Express Lines, Ltd. v. Higgins
281 F.3d 383 (Third Circuit, 2002)
Fowler v. UPMC SHADYSIDE
578 F.3d 203 (Third Circuit, 2009)
In Re Pameco Corp.
356 B.R. 327 (S.D. New York, 2006)
Burtch v. Huston (In Re USdigital, Inc.)
443 B.R. 22 (D. Delaware, 2011)
In Re Sunset Aviation, Inc.
468 B.R. 641 (D. Delaware, 2011)
Perry v. Merit Systems Protection Bd.
582 U.S. 420 (Supreme Court, 2017)
Ana Alpizar-Fallas v. Frank Favero
908 F.3d 910 (Third Circuit, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Center City Healthcare, LLC v. McKesson Plasma & Biologics LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/center-city-healthcare-llc-v-mckesson-plasma-biologics-llc-deb-2022.